Enhanced mucosal SARS-CoV-2 immunity after heterologous intramuscular mRNA prime/intranasal protein boost vaccination with a combination adjuvant

• Published in: Molecular therapy Vol. 32; no. 12; pp. 4448 - 4466
• Main Authors: Laghlali, Gabriel, Wiest, Matthew J., Karadag, Dilara, Warang, Prajakta, O’Konek, Jessica J., Chang, Lauren A., Park, Seok-Chan, Yan, Vivian, Farazuddin, Mohammad, Janczak, Katarzyna W., García-Sastre, Adolfo, Baker, James R., Wong, Pamela T., Schotsaert, Michael
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 04.12.2024; American Society of Gene & Cell Therapy
• Subjects: Adjuvants, Immunologic - administration & dosage; Adjuvants, Vaccine - administration & dosage; Administration, Intranasal; Animals; Antibodies, Neutralizing - immunology; Antibodies, Viral - immunology; COVID-19 - immunology; COVID-19 - prevention & control; COVID-19 Vaccines - administration & dosage; COVID-19 Vaccines - immunology; Female; Humans; Immunity, Mucosal; Immunization, Secondary; Injections, Intramuscular; intranasal vaccination; Mice; mRNA vaccines; mRNA Vaccines - immunology; mucosal adjuvants; mucosal immunization; Original; prime/pull; SARS-Cov-2; SARS-CoV-2 - immunology; Spike Glycoprotein, Coronavirus - genetics; Spike Glycoprotein, Coronavirus - immunology; tissue-resident memory T cells; Vaccination - methods; mucosal immunization; SARS-Cov-2; intranasal vaccination; prime/pull; mRNA vaccines; mucosal adjuvants; tissue-resident memory T cells
• ISSN: 1525-0016; 1525-0024; 1525-0024
• DOI: 10.1016/j.ymthe.2024.10.016

Current COVID-19 mRNA vaccines delivered intramuscularly (IM) induce effective systemic immunity, but with suboptimal immunity at mucosal sites, limiting their ability to impart sterilizing immunity. There is strong interest in rerouting immune responses induced in the periphery by parenteral vaccination to the portal entry site of respiratory viruses, such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), by mucosal vaccination. We previously demonstrated the combination adjuvant, NE/IVT, consisting of a nanoemulsion (NE) and an RNA-based RIG-I agonist (IVT) induces potent systemic and mucosal immune responses in protein-based SARS-CoV-2 vaccines administered intranasally (IN). Herein, we demonstrate priming IM with mRNA followed by heterologous IN boosting with NE/IVT adjuvanted recombinant antigen induces strong mucosal and systemic antibody responses and enhances antigen-specific T cell responses in mucosa-draining lymph nodes compared to IM/IM and IN/IN prime/boost regimens. While all regimens induced cross-neutralizing antibodies against divergent variants and sterilizing immunity in the lungs of challenged mice, mucosal vaccination, either as homologous prime/boost or heterologous IN boost after IM mRNA prime, was required to impart sterilizing immunity in the upper respiratory tract. Our data demonstrate the benefit of hybrid regimens whereby strong immune responses primed via IM vaccination are rerouted by IN vaccination to mucosal sites to provide optimal protection against SARS-CoV-2. [Display omitted] Wong, Schotsaert, and colleagues demonstrate a rationally designed IN vaccine composed of a nanoemulsion (NE) and RIG-I agonist (IVT) adjuvant with SARS-CoV-2 subunit antigens effectively “pulls” and boosts immune responses parenterally primed by SARS-CoV-2 mRNA vaccines. This heterologous prime-pull strategy fosters enhanced local mucosal immune responses and optimally shapes protective systemic immunity.